Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | PAM | P19021 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 4/20 | 0.46 |
| ▸ | CES1 | P23141 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4449355 | 0.98 | DGKA (0.55) | ALDH1A1DGKAMAPTMAPK1LMNA | |
| SCHEMBL9389473 | 0.98 | DGKA (0.55) | ALDH1A1DGKAMAPTMAPK1LMNA | |
| SCHEMBL1671447 | 0.98 | DGKA (0.55) | ALDH1A1DGKAMAPTMAPK1LMNA | |
| SCHEMBL8845364 | 0.98 | DGKA (0.55) | ALDH1A1DGKAMAPTMAPK1LMNA | |
| SCHEMBL28663735 | 0.98 | DGKA (0.55) | ALDH1A1DGKAMAPTMAPK1LMNA | |
| SCHEMBL6561781 | 0.98 | ALDH1A1 (0.54) | ALDH1A1DGKAMAPTMAPK1LMNA | |
| SCHEMBL2116875 | 0.96 | DGKA (0.57) | ALDH1A1DGKAMAPTMAPK1LMNA | |
| SCHEMBL11047570 | 0.96 | DGKA (0.57) | ALDH1A1DGKAMAPTMAPK1LMNA | |
| SCHEMBL1673172 | 0.96 | DGKA (0.57) | ALDH1A1DGKAMAPTMAPK1LMNA | |
| SCHEMBL3172247 | 0.96 | DGKA (0.57) | ALDH1A1DGKAMAPTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099436-A1 | DRUG FOR TREATING TINNITUS | UNIV SOUTH FLORIDA (US) | 2025-03-27 | — | — | US | disclosed |
| US-12194026-B2 | Drug for treating tinnitus | UNIVERSITY OF SOUTH FLORIDA (US) | 2025-01-14 | — | — | US | disclosed |
| EP-3870159-B1 | DRUG FOR TREATING TINNITUS | UNIV SOUTH FLORIDA (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20210393596-A1 | DRUG FOR TREATING TINNITUS | SCOTT, LUISA LYNN | 2021-12-23 | — | — | US | disclosed |
| EP-1231877-A4 | TRANSDERMAL ADMINISTRATION OF HUPERZINE | XEL HERBACEUTICALS (US) | 2009-03-18 | — | — | EP | disclosed |
| CN-100409847-C | Transdermal delivery system for alkaloids of aconitum species | XEL HERBACEUTICALS (US) | 2008-08-13 | — | — | CN | disclosed |
| CN-1240384-C | Transdermal administration of huperzine | XEL HERBACEUTICALS INC (US) | 2006-02-08 | — | — | CN | disclosed |
| US-20050187212-A1 | Pharmaceutical composition for topical delivery of meloxicam | NIPPON BOEHRINGER INGELHEIM CO., LTD. (DE) | 2005-08-25 | — | — | US | disclosed |
| EP-1542695-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL DELIVERY OF MELOXICAM COMPRISING AN AMINE OR AMINE AS PENETRATION ENHANCER. | Nippon Boehringer Ingelheim Co., Ltd. (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-6896898-B1 | Transdermal delivery system for alkaloids of aconitum species | XEL HERBACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1383464-A4 | NAIL COMPOSITIONS AND METHODS OF ADMINISTERING SAME | WATSON PHARMACEUTICALS INC (US) | 2004-05-12 | — | — | EP | disclosed |
| WO-2004026313-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL DELIVERY OF MELOXICAM COMPRISING AN AMINE OR AMINE AS PENETRATION ENHANCER. | NIPPON BOEHRINGER INGELHEIM CO., LTD. (JP) | 2004-04-01 | — | — | WO | disclosed |
| EP-1383464-A1 | NAIL COMPOSITIONS AND METHODS OF ADMINISTERING SAME | Watson Pharmaceuticals, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| CN-1450883-A | Transdermal delivery system for alkaloids of aconitum species | XEL HERBACEUTICALS (US) | 2003-10-22 | — | — | CN | disclosed |
| CN-1450882-A | Transdermal administration of huperzine | XEL HERBACEUTICALS INC (US) | 2003-10-22 | — | — | CN | disclosed |
| US-6585963-B1 | Nail compositions and methods of administering same | WATSON PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | disclosed |
| WO-2002083084-A1 | NAIL COMPOSITIONS AND METHODS OF ADMINISTERING SAME | WATSON PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1231877-A1 | TRANSDERMAL ADMINISTRATION OF HUPERZINE | XEL Herbaceuticals (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001035883-A1 | TRANSDERMAL DELIVERY SYSTEM FOR ALKALOIDS OF ACONITUM SPECIES | XEL HERBACEUTICALS (US) | 2001-05-25 | — | — | WO | disclosed |
| WO-2001032115-A1 | TRANSDERMAL ADMINISTRATION OF HUPERZINE | XEL HERBACEUTICALS (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393596-A1 | DRUG FOR TREATING TINNITUS | CHAT, SLC18A2, TRPV1 | ALDH1A1 381/4885DGKA 2013/4885MAPT 803/4885 |
| US-20050187212-A1 | Pharmaceutical composition for topical delivery of meloxicam | PTGER1, PTGER2, ALOX12 | ALDH1A1 1281/4885DGKA 4823/4885MAPT 1943/4885 |
| US-20250099436-A1 | DRUG FOR TREATING TINNITUS | CHAT, SLC18A2, TRPV1 | ALDH1A1 381/4885DGKA 2013/4885MAPT 803/4885 |
| US-12194026-B2 | Drug for treating tinnitus | CHAT, SLC18A2, TRPV1 | ALDH1A1 381/4885DGKA 2013/4885MAPT 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.